The Global Synthetic Drugs Assessment 2020 provides an analysis of the global synthetic drugs market.
Inequality in Smoking Cessation Clinical Trials – Exclusion of Smokers with Mental Health Disorders (MHDs)
The Global Drug Survey uses an anonymous online survey to conduct the world’s biggest drug survey.
The annual GDS survey runs from the middle of November each year for approximately 6 weeks.
GDS partners with global media giants to act as...
The GDS Special Edition on COVID-19 was developed as part of a global effort to better understand the impact of the pandemic on people’s lives with a specific focus on the use of alcohol and other drugs, mental health and relationships.
Ov...
Pandemics and health emergencies like the current COVID-10 outbreak, can cost many lives and pose additional risks to the global economy and overall security and stability. Ensuring continued access to health care during a pandemic...
"Open Access" resources do not require a university affiliation or expensive journal subscriptions. They are available to anyone with an internet connection.
This portal, developed with input from the Hubert H. Humphrey Fellows at...
The COVID-19 pandemic and the restrictions associated with it have changed people’s lives in almost all countries. However, very few realize how the lives of people with drug use disorders – who are among the most vulnerable and in need of...
A Regional three-day training for trainers (ToT) on Course 9 “Advanced Pharmacology and Substance Use Disorders” of the Advanced Level of the Universal Treatment Curriculum for Substance Use Disorders (UTC training package) was launched via...
In this video, Charlotte Sisson, Senior Foreign Affairs Officer within the Office of Global Programmes and Policy in the Bureau for International Narcotics and Law Enforcement Affairs at the U.S. Department of State, introduces the audience...
